1343-OR: Continuous Glucose Monitoring vs. Blood Glucose Monitoring in Patients with Type 2 Diabetes Managed on Insulin in Primary Care: The GluCoCare Study
Randomized trial evaluates A1C improvement with continuous glucose monitoring in insulin-managed type 2 diabetes in primary care, suggesting effective monitoring strategies.
Key Points
Evaluate the effectiveness of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) in type 2 diabetes (T2D) patients managed with insulin in primary care.
Two-arm trial cluster-randomized by clinic attendance: 25 clinics per intervention group.
Participated 360 adults, aged 18-75, with A1C of 7.5-12%, over 12 months of routine care.
Compared differential change in A1C and diabetes distress scores from baseline to 12 months.
CGM significantly improved A1C to 7.97% (decrease of -0.80%) compared to BGM at 8.30% (decrease of -0.47%); adjusted mean difference -0.33% (95% CI, -0.59 to -0.07; P=0.012).
No significant difference in diabetes distress scale scores between groups.
Blinded CGM showed a non-significant improvement in time in range 70-180 mg/dL (∆ 4.6%, p=0.14).